Be The Investor ResearchNike's $45 and $28 Targets Frame Its November Test
Barclays raised its Nike target to $45 while Wolfe began coverage at $28. Their disagreement turns on whether management can show a credible return to revenue growth at Investor Day.
Two new analyst calls put a wide range around Nike's turnaround. Barclays raised its price target to $45 from $37 on October 22 after meeting management, while Wolfe Research began coverage with an Underperform rating and a $28 target. Nike closed that day at $38.32.
The disagreement is not about a small quarterly beat. It is about how long investors should wait for revenue growth to return. Barclays analyst Adrienne Yih reportedly left earnings estimates unchanged and raised the valuation multiple, calling the shares near a bottom. She still expects the stock to remain rangebound until growth becomes visible. Wolfe's lower target assigns a steeper penalty to the same uncertainty.
Nike's own guidance sets a low but demanding base. Management expects fiscal 2027 adjusted earnings per share of $1.15 to $1.35, excluding about $0.15 of costs from the Pace productivity program. Nike also guided to a high-single-digit revenue decline for the year. TIKR said consensus fiscal 2027 revenue estimates fell 5.6% to $42.8 billion after the October 1 report, while fiscal 2028 estimates fell 7.5% to $43.3 billion.
The product reset explains part of the decline. Nike reduced Dunk revenue by nearly 50% in its fiscal first quarter, creating an approximately $200 million headwind in Sportswear. Management also said some older, high-volume footwear sold more slowly than expected. At the same time, Studio Fleece was the company's best-performing apparel collection of the quarter, and several newer running-inspired Sportswear styles grew at double-digit rates.
Those mixed results make the next strategy update unusually important. Nike will hold Investor Day on November 16 and 17, with main presentations webcast on November 17. Investors will be looking for a dated path back to revenue growth, evidence that new products can replace shrinking lifestyle franchises, and a clear explanation of how much of the planned $2.5 billion in Pace savings will reach earnings rather than be reinvested.
The $45 case does not require Nike to return immediately to its former growth rate, but it does require management to stop estimate cuts and make fiscal 2028 growth credible. The $28 case becomes more plausible if the company pushes recovery farther out or if wholesale partners continue to work through excess inventory.
A valuation model cited by TIKR produced a much higher figure near $90, but it assumed roughly 4% annual revenue growth, well above the cited consensus rate of about 1.7% through fiscal 2031. That gap is too large to treat the model as a current price target. For now, the useful range is the analysts' $28 to $45 debate, and Investor Day is the first chance for Nike to narrow it with operating evidence.